Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
February 25, 2025 9:45 AM ESTRodman & Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)
The analyst comments "Bicycle Therapeutics plc (BCYC; Buy) provided its 4Q24 and FY2024 business updates this morning before the markets opened. Recall that Bicycles clinical pipeline consists of Bicycle-Toxin Conjugates (BTC) and Bicycle-radio conjugates (BRC) against solid tumors.... More
